Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.

Abdulaali Almutairi,Nimer Alsaid,Mok Oh,Hani M. Babiker,Ali McBride,Ivo Abraham

Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.

2018

Abdulaali Almutairi
Nimer Alsaid
Mok Oh
Hani M. Babiker
Ali McBride
Ivo Abraham

e21545Background: A recent trial comparing T-vec+Ipi vs Ipi found no differential benefit in progression-free survival (PFS) (HR 0.83, 95%CI 0.56–1.23), but noted objective response rates (ORR) of ...

Keywords:

Physical therapy
Melanoma
Ipilimumab
Talimogene laherparepvec
Cancer research
Medicine
objective response
Oncology
in patient
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations